These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 30617728)

  • 1. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
    Ahn T; Roberts MJ; Abduljabar A; Joshi A; Perera M; Rhee H; Wood S; Vela I
    Mol Imaging Biol; 2019 Oct; 21(5):799-807. PubMed ID: 30617728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
    Evangelista L; Basso U; Maruzzo M; Novara G
    Eur Urol Focus; 2020 Jan; 6(1):146-150. PubMed ID: 30120074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of
    Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
    Pathmanathan S; Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Wong D; McBean R; Marsh P; Goodman S; Dhiantravan N; Esler R; Dunglison N; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Goh JC; Gan CL; Roberts MJ
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):295-303. PubMed ID: 37592084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
    Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
    Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.
    Sadaghiani MS; Baskaran S; Gorin MA; Rowe SP; Provost JC; Teslenko I; Bilyk R; An H; Sheikhbahaei S
    J Nucl Med; 2024 Jul; 65(7):1007-1012. PubMed ID: 38782453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
    Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
    Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.
    Urso L; Castello A; Rocca GC; Lancia F; Panareo S; Cittanti C; Uccelli L; Florimonte L; Castellani M; Ippolito C; Frassoldati A; Bartolomei M
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1299-1311. PubMed ID: 35217902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT).
    Tariq A; McGeorge S; Pearce A; Rhee H; Wood S; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Jun; 40(6):276.e1-276.e9. PubMed ID: 35466037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis.
    Singhal T; Singh P; Parida GK; Agrawal K
    Ann Nucl Med; 2024 Mar; 38(3):176-187. PubMed ID: 38340144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
    Pozzessere C; Bassanelli M; Ceribelli A; Rasul S; Li S; Prior JO; Cicone F
    Curr Urol Rep; 2019 Oct; 20(11):68. PubMed ID: 31605269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma.
    Udovicich C; Callahan J; Bressel M; Ong WL; Perera M; Tran B; Azad A; Haran S; Moon D; Chander S; Shaw M; Eapen R; Goad J; Lawrentschuk N; Murphy DG; Hofman M; Siva S
    Eur Urol Open Sci; 2022 Oct; 44():60-68. PubMed ID: 36185587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
    Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of
    Raveenthiran S; Esler R; Yaxley J; Kyle S
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2280-2288. PubMed ID: 31332498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted
    Meyer AR; Carducci MA; Denmeade SR; Markowski MC; Pomper MG; Pierorazio PM; Allaf ME; Rowe SP; Gorin MA
    Ann Nucl Med; 2019 Aug; 33(8):617-623. PubMed ID: 31147927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
    Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
    Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid Tumor Washout of 177 Lu-PSMA Radioligand in Renal Cell Carcinoma.
    Zhang J; Schuchardt C; Chen X; Baum RP
    Clin Nucl Med; 2023 Aug; 48(8):732-734. PubMed ID: 37276536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
    Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
    Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort.
    Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Pelecanos A; Gan CL; Goh JC; Wong D; McBean R; Marsh P; Goodman S; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Eur Urol Focus; 2024 Sep; 10(5):770-778. PubMed ID: 38195354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.